4-溴-3-甲基苯乙酸 | 215949-57-8

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-3-甲基苯乙酸
• 英文名称: 2-(4-bromo-3-methylphenyl)acetic acid
• CAS: 215949-57-8
• 化学式: C₉H₉BrO₂
• 分子量: 229.073
• InChiKey: LHFFNLRLDVODNC-UHFFFAOYSA-N

物化性质

• 熔点：
  81℃
• 沸点：
  338℃
• 密度：
  1.533
• 闪点：
  158℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  4-溴-3-甲基苯乙酸 在 aluminum (III) chloride 、 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 6-bromo-5-methyl-3,4-dihydronaphthalene-2(1H)-one
  参考文献：
  名称：

  Regioisomerism in the Synthesis of a Chiral Aminotetralin Drug Compound: Unraveling Mechanistic Details and Diastereomer-Specific In-Depth NMR Investigations

  摘要：

  During chemical process development of a novel 2-aminotetralin derivative intended for use as an antidepressant, scrutiny of the byproduct present in the drug molecule revealed a set of regioisomers. Detailed studies showed that this impurity issue originated from an early synthetic step in which a brominated tetralone motif was generated in a ring-closing protocol. It was found that this reaction was accompanied by a migration of the aromatic bromo substituent via different bromonium species along two discrete pathways. This example of the halogen dance reaction resulted in the formation of a series of tetralone impurities with a bromine distributed across all available aromatic positions of the tetralin nucleus. Subsequently, when subjected to reductive amination conditions, each of these tetralones gave rise to pairs of aminotetralins in a diastereomeric relationship. NMR investigations revealed that the alicyclic portion of the compounds thus formed displayed very complex signal patterns, which required further in-depth studies using a variety of sophisticated techniques. As a result, a deep insight into the structural features of the current 2-aminotetralin family was obtained, which is emphasized by the definition of a novel "0.2 ppm rule" allowing the absolute configuration at tetralin C-2 to be determined.

  DOI：

  10.1021/jo300277y
• 作为产物：
  描述：

  2-[4-溴-间甲苯基]-乙酰胺 生成 4-溴-3-甲基苯乙酸
  参考文献：
  名称：

  Willgerodt, Journal fur praktische Chemie (Leipzig 1954), 1909, vol. <2> 80, p. 189

  摘要：

  DOI：

文献信息

• Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists
  作者：Nannan Sun、Yafei Huang、Mingcheng Yu、Yunpeng Zhao、Ji-An Chen、Chenyu Zhu、Meiqi Song、Huimin Guo、Qiong Xie、Yonghui Wang

  DOI：10.1016/j.ejmech.2020.112536

  日期：2020.9

  GSK805 (1) is a potent RORγt inverse agonist, but a drawback of 1 is its low solubility, leading to a limited absorption in high doses. We have explored detailed structure-activity relationship on the amide linker, biaryl and arylsulfonyl moieties of 1 trying to improve solubility while maintaining RORγt activity. As a result, a novel series of carboxyl-containing biaryl urea derivatives was discovered

  GSK805（1）是一种强效RORγt反向激动剂，但缺点1是它的低溶解度，从而导致在高剂量有限的吸收。我们已经探索了1的酰胺连接基，联芳基和芳基磺酰基部分的详细结构-活性关系，试图在保持RORγt活性的同时提高溶解度。结果，发现了一系列新颖的含羧基联芳基脲衍生物，作为具有改进的类药物性质的有效RORγt反向激动剂。化合物3i显示了强大的RORγt抑制活性和亚型选择性，在RORγFRET分析中的IC 50为63.8 nM，在基于细胞的RORγ-GAL4启动子报告子分析中为85 nM。合理的3i抑制活性在小鼠Th17细胞分化试验中也获得了抑制（在0.3μM时抑制76％）。此外，与1相比，3i在pH 7.4时具有大大改善的水溶解度，表现出体面的小鼠PK曲线，并在咪喹莫特诱导的牛皮癣小鼠模型中表现出一定的体内功效。
• [EN] LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS D'ACIDE LYSOPHOSPHATIDIQUE
  申请人：INTERMUNE INC

  公开号：WO2013025733A1

  公开（公告）日：2013-02-21

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  提供了化合物、制备这种化合物的方法、包含这种化合物的药物组合物和药物，以及使用这种化合物治疗、预防或诊断与一种或多种赖氨酸磷脂酸受体相关的疾病、紊乱或状况的方法。
• [EN] LILY OF THE VALLEY ODORANT<br/>[FR] SUBSTANCE ODORANTE AU PARFUM DE MUGUET
  申请人：FIRMENICH & CIE

  公开号：WO2019141761A1

  公开（公告）日：2019-07-25

  The present invention concerns the use as perfuming ingredient of a compound of formula (I) in the form of any one of its stereoisomers or a mixture thereof, and wherein X represents a CHO group when R1 represents a C1-2 alkyl group or X represents a CH(R6)CHO group when R1 represents a hydrogen atom or a C1-2 alkyl group; each R2, R3, R4, R5 and R6 represents, independently from each other, a hydrogen atom or a C1-2 alkyl group; or R3 and R4 represent, when taken together, a ethanediyl group; and -C(R3)(R4)-CH(R5)-OH group is, relative to position 1, an ortho, a meta, a para substituent of the aromatic ring or a mixture thereof. Moreover, the compound of formula (I) as part of a perfuming composition or of a perfumed consumer product is also part of the present invention.

  本发明涉及一种化合物作为香料成分，其化学式为(I)，以其立体异构体或其混合物的形式存在，其中X代表CHO基团，当R1代表C1-2烷基基团时，或者X代表CH(R6)CHO基团，当R1代表氢原子或C1-2烷基基团时；每个R2、R3、R4、R5和R6独立地代表氢原子或C1-2烷基基团；或者当一起取时，R3和R4代表乙二基基团；而-C(R3)(R4)-CH(R5)-OH基团相对于位置1，是芳香环的邻位、间位、对位取代基或其混合物。此外，化合物的化学式(I)作为香料组合物或香水消费产品的一部分也属于本发明。
• [EN] LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DU RÉCEPTEUR 1 DE L'ACIDE LYSOPHOSPHATIDIQUE (LPAR1)
  申请人：LILLY CO ELI

  公开号：WO2019041340A1

  公开（公告）日：2019-03-07

  A compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described.

  化合物的结构式（I）或其药用盐，使用方法和制备方法的描述。
• [EN] N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS<br/>[FR] ACÉTAMIDES À SUBSTITUTION N-(HÉTÉRO)ARYL, 2-(HÉTÉRO)ARYLE POUR UNE UTILISATION EN TANT QUE MODULATEURS DE LA VOIE DE SIGNALISATION WNT
  申请人：IRM LLC

  公开号：WO2010101849A1

  公开（公告）日：2010-09-10

  The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A1, A2, B, Y and Z all represent rings.

  本发明涉及公式1和2的化合物，以及使用这些化合物调节Wnt信号通路的方法，其中A1、A2、B、Y和Z都代表环。